AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.
研究兴趣

论文共 144 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies
David J Stewart,Tim Ramsay,Vishal Navani,Geoffrey Liu, Di Maria Jiang,Gerald Batist
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 8 (2024): 973-974
引用0浏览0WOS引用
0
0
Abstract CT206: A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
Christopher F. Theriau, Jamie Feng,Lawson Eng,Frances A. Shepherd, Mary DeCarolis, Vivian Glenns,Swati Kulkarni, R Vandermeer, Urszula Zurawska-Fortin,Desirée Hao,Lisa W. Le, Isabel Wozniczka,
Cancer Researchno. 8_Supplement (2023): CT206-CT206
引用0浏览0引用
0
0
Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study
M. Garcia Pardo,K. Czarnecka,J. H. Law, Z. J. Fan,T. K. Waddell, K. Yasufuku,G. Liu,L. L. Donahoe,A. Pierre, L. W. Le, T. Gunasegaran, N. Ghumman,
Journal of Thoracic Oncologyno. 11 (2023): S245-S246
引用0浏览0引用
0
0
A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
Christopher F. Theriau, Jamie Feng,Lawson Eng,Frances A. Shepherd, Mary DeCarolis, Vivian Glenns,Swati Kulkarni, Rachel VanderMeer, Urszula Zurawska-Fortin,Desiree Hao,Lisa Le, Isabel Wozniczka,
CANCER RESEARCHno. 8 (2023)
引用0浏览0引用
0
0
加载更多
作者统计
  • 合作者
  • 学生
  • 导师
暂无相似学者，你可以通过学者研究领域进行搜索筛选
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn